Clinical Trial Update: Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease [Phase 1]

View source ↗

Summary

Phase 1 safety, tolerability, and pharmacokinetic study of EVP-6124 in Alzheimer's disease completed; results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• EVP-6124

Snippet

Sponsor: FORUM Pharmaceuticals Inc | Conditions: Alzheimer's Disease, Central Nervous System Diseases | Phase 1 | Status: COMPLETED | Results posted: 2011-07-14